We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CellaVision Introduces Analyzers into the Japanese Market

By LabMedica International staff writers
Posted on 03 Oct 2008
Print article
CellaVision (Lund, Sweden) develops and sells digital morphology (DM) products for the routine analysis of blood and other body fluids. In March 2008, the company established a subsidiary in Japan--CellaVision Japan K.K. (Yokohama, Japan). Official approval has been given for the subsidiary to market the company's analyzers in Japan.

The Japanese authority, Pharmaceuticals and Medical Device Agency (PMDA) issued the product registration. The Japanese subsidiary was opened during a ceremony at the Swedish Embassy in Tokyo on the September 11, 2008. On October 9-11, 2008, CellaVision's products will be presented at Japan's largest convention for clinical laboratory products, the Japanese Society for Clinical Laboratory Automation (JSCLA). Around 7,000 participants in the field of clinical chemistry are expected to attend.

"The establishment of our Japanese subsidiary is advancing according to plan and it is satisfying to now be active on the Japanese market. We hope to be completely operative before the end of the year,” said CellaVision's CEO Yvonne Martensson. "It is important for us to meet potential clients on site in order to demonstrate how also Japanese laboratories can benefit from CellaVision's digital morphology technology. We see considerable potential in the Japanese market.”

There are approximately 9,000 hospitals and 900 commercial laboratories in Japan, which has large potential for medical technology products in general. CellaVision will focus primarily on the 1,000 larger hospital and commercial laboratories that will benefit the most from automating their processes.

CellaVision develops software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white and red blood cell morphology, software for education, and for quality assurance of differentials.

Related Links:
CellaVision
Japanese Society for Clinical Laboratory Automation


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Hepatitis B Virus Test
HBs Ab – ELISA
New
FLU/RSV Test
Humasis FLU/RSV Combo

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.